Your browser is no longer supported. Please, upgrade your browser.
IHE iShares U.S. Pharmaceuticals ETF daily Stock Chart
iShares U.S. Pharmaceuticals ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week1.68%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-1.06%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-1.59%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.71 Perf Half Y5.37%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year4.59%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range129.20 - 158.11 Perf YTD6.76%
Dividend1.31 P/FCF- EPS past 5Y- ROI- 52W High-4.51% Beta-
Dividend %0.87% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low16.86% ATR1.48
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)52.15 Volatility0.67% 0.88%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.03 Prev Close149.91
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume14.90K Price150.98
Recom- SMA200.28% SMA500.12% SMA2002.27% Volume15,372 Change0.71%
May-18-17 07:37AM  Inside Bristol-Myers Squibbs Valuation after the 1Q17 Earnings Market Realist
May-17-17 05:37PM  The Latest Market Trends Every Biopharma Investor Needs to Know Zacks
May-09-17 07:35AM  Pfizers Corporate and Pipeline Developments in 1Q17 Market Realist
May-08-17 09:06AM  Pfizer: Why Revenues Fell in 1Q17 for Some Products Market Realist
May-05-17 02:17PM  Analyzing Pfizers 1Q17 Earnings Market Realist
May-01-17 01:21PM  Pfizers 1Q17 Earnings: Analysts Estimates Market Realist
Apr-27-17 07:36AM  Analysts Ratings and Recommendations for Bristol-Myers Squibb Market Realist
Apr-24-17 02:20PM  Why some investors aren't thrilled about Becton Dickinson buying C.R. Bard Yahoo Finance Video
02:20PM  Why medical device stocks may rise if Obamacare is repealed Yahoo Finance Video
11:37AM  Stocks soar after French elections ahead of busiest earnings week in 10 years Yahoo Finance
Apr-21-17 09:06AM  How Will Eli Lillys Alimta and Other Oncology Products Perform? Market Realist
07:36AM  Johnson & Johnsons Pharmaceuticals Segments 1Q17 Earnings Market Realist
Apr-19-17 10:55AM  Lackluster J&J Q1 Pushes Healthcare ETFs Down Zacks
Apr-11-17 01:05PM  The Larger Aims of Obamacare: An Overview Market Realist
11:29AM  The Hybrid US Healthcare System: An Overview Market Realist
Apr-05-17 08:32AM  There Is Value To Be Had With The Right Healthcare ETFs Benzinga
08:32AM  There Is Value To Be Had With The Right Healthcare ETFs
Apr-04-17 12:24PM  There's Value in Healthcare ETFs Investopedia
12:24PM  There's Value in Healthcare ETFs
09:06AM  Whats Pfizers Financial Guidance for 2017? Market Realist
09:06AM  Whats Pfizers Financial Guidance for 2017?
Mar-29-17 07:36AM  What Wall Street Analysts Recommend for Merck Market Realist
07:36AM  What Wall Street Analysts Recommend for Merck
Mar-15-17 04:33PM  Should You Buy Pharma ETFs Now? Zacks
04:33PM  Should You Buy Pharma ETFs Now?
Mar-13-17 10:37AM  Johnson & Johnsons Business Segment Performance Market Realist
10:37AM  Johnson & Johnsons Business Segment Performance
Mar-08-17 04:20PM  Why Health Care Is The Top Sector Of 2017
04:20PM  Why Health Care Is The Top Sector Of 2017
Mar-07-17 03:21PM  Analysts Scratch Their Heads Over Trump Drug Price Tweet The Wall Street Journal
03:21PM  Analysts Scratch Their Heads Over Trump Drug Price Tweet at The Wall Street Journal
11:34AM  Trump Tweets And Drug Stocks Fall
11:34AM  Trump Tweets And Drug Stocks Fall at
09:58AM  Healthcare ETFs in Focus on Obamacare Replacement Plan
09:48AM  Trump's Latest Drug Pricing Tweet Hits Biotech Stocks at The Wall Street Journal
Mar-06-17 09:06AM  How These Recent Developments Could Affect Mylan
Feb-27-17 10:38AM  Pfizers Products with Falling Revenues in 4Q16
Feb-24-17 10:36AM  Wall Street Analysts Estimates for Merck & Co.
Feb-22-17 07:37AM  Merck & Co. Reported Flat Operational Revenues in 4Q16
Feb-06-17 09:55AM  Q4 Earnings Faring Well for Pharma ETFs
Feb-01-17 01:19PM  Novartiss 4Q16 Earnings Meet Analysts Estimates
01:10PM  How to Play Pfizer's Fourth-Quarter Results With ETFs
Jan-31-17 10:36AM  Eliquis: Bristol-Myers Squibbs Key Cardiovascular Drug
Jan-30-17 11:45AM  Bristol-Myers Squibb: 4Q16 Earnings Show Growth
10:35AM  What Are Analysts Future Estimates for Johnson & Johnson?
Jan-26-17 12:00PM  Johnson & Johnson Reports Growth in 4Q16
Jan-20-17 09:07AM  How Did JNJs Pharmaceuticals Segment Perform in 4Q16?
Jan-19-17 04:06PM  What Lies Ahead for Pharma ETFs?
Jan-17-17 11:16AM  Biotech ETFs: When Will The Pain End? at
Jan-13-17 09:06AM  Mylans Recent Commercial and Product Developments
Jan-12-17 12:01PM  Biotech ETFs Continue To Bleed at
Jan-11-17 05:05PM  Mylans EpiPen Controversy: Is It a Brand or a Generic?
12:09PM  Biotech, Pharma ETFs Sink; Trump Promises "Bidding Procedures" at
Dec-21-16 11:21AM  Top 5 Pharmaceutical ETFs for 2016 at Investopedia
Dec-20-16 09:06AM  Horizon Pharmas Orphan Drug Segment: 3Q16 Performance
Dec-15-16 08:00AM  Trending: Transportation and Steel Industries Prepare for Trumponomics
Dec-13-16 09:36AM  Exploring Avelumabs Opportunities in the PD-1/PD-L1 Space
Dec-12-16 11:05AM  Johnson & Johnsons Consumer Segment in 3Q16
08:06AM  How Did Pfizers Innovative Health Business Perform in 3Q16?
Dec-09-16 11:06AM  Johnson & Johnsons Business Segment Performance in 3Q16
Dec-02-16 04:05PM  Two Nano-Cap Pharma Stocks To Watch Right Now at Insider Monkey
Nov-29-16 10:05AM  Pfizer Divests Hospiras Infusion System Business to ICU Medical
Nov-17-16 12:18PM  Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios
Nov-16-16 05:04PM  Novartiss 3Q16 Earnings Surpass Analyst Estimates
Nov-09-16 10:08AM  Trump Victory Big For Biotech at +6.89%
Nov-08-16 10:04AM  Pfizers 3Q16 Earnings: Profitability and Financial Guidance
08:04AM  Understanding Pfizers Products with Declining Sales
Nov-07-16 10:02AM  Healthcare ETFs in the Spotlight as Election Approaches
Nov-01-16 08:04AM  Behind the Recent Developments in Pfizers 3Q16 Estimates
Oct-28-16 12:07PM  3 ETFs to Buy if You Think Pfizer Will Beat Earnings
Oct-25-16 11:45AM  Bristol-Myers Squibbs 3Q16 Earnings: Whats Expected
10:04AM  Analyzing Future Estimates for Johnson & Johnson
Oct-21-16 10:05AM  A Look at Johnson & Johnsons Segment-Wise Performance in 3Q16
Oct-14-16 11:04AM  How Much Is Pfizers Return Potential?
10:10AM  Johnson & Johnsons 3Q16 Earnings: What to Expect
10:04AM  Pfizers Divestment of Hospira Infusion Systems
Oct-11-16 08:04AM  What Do Analysts Have to Say about Bristol-Myers Squibb?
Oct-03-16 08:05AM  Medicare Negotiations Would Lead to Huge Cost Savings
Sep-30-16 03:04PM  Analyzing Donald Trumps Free-Market Healthcare
01:04PM  How Does Hillary Clinton Plan to Tame Drug Prices?
11:15AM  Generic Drugs Are Crucial in Cost Savings and Accessibility
Sep-29-16 06:04PM  The Pfizer-Anacor Deal: A Review
Sep-27-16 02:20PM  Getting Into The Drug Business: From NDAs To PDUFA Dates
Sep-23-16 05:04PM  Youve Heard about the EpiPen Debacle, but Have You Heard This?
Sep-21-16 10:04AM  How Procysbi Fits into Horizons Existing Orphan Drug Portfolio
Sep-12-16 10:04AM  How Can Pfizer Revive Its Essential Health Business?
09:30AM  The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical
Sep-09-16 03:39PM  Will a Clinton Presidency Spell Doom for Pharma ETFs?
Sep-01-16 11:04AM  Why Pfizers Vaccines Business Is Declining
Aug-31-16 11:05AM  Will Xtandi Fuel Pfizers Top-Line Growth?
10:58AM  Biotech Leads the Way in Health Care Stocks to Boost 401(k) Returns
Aug-30-16 02:04PM  Analyzing Johnson & Johnsons Business Segments
Aug-22-16 12:01PM  ETFs in Focus on Pfizer's Medivation Acquisition
Aug-11-16 11:04AM  Pfizers Products with Decreasing Revenues
Aug-05-16 09:05AM  Falls Continue in Specialty Generics and Nuclear Imaging
Aug-03-16 12:22PM  Pharma ETFs Soaring on Solid Q2 Earnings
Jul-27-16 09:04AM  What Do Analysts Estimate for Johnson & Johnson?
Jul-22-16 01:14PM  How Did Johnson & Johnsons Segments Perform in 2Q16?
Jul-14-16 10:06AM  How Can Celators Portfolio Complement Jazz Pharmaceuticals?
Jul-04-16 11:06AM  Insights into Pfizers Profitability and Financial Guidance
The investment seeks to track the investment results of Dow Jones U.S. Select Pharmaceuticals Index. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying fund measures the performance of the pharmaceuticals sector of the U.S. equity market and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund is non-diversified.